SBP GROUP (01177): Latest research results for TQ-A3334 "TLR7 agonist" and Bepirovirsen "ASO" will be presented at the 2026 AASLD
China Biopharmaceutical (01177) announced that a clinical study result of TQ-A3334 (TLR7 agonist), a National Class 1 innovative drug independently developed by the Company's subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Chia Tai Tianqing), has been selected as a late-breaking abstract (LBA) for the 2026 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) and will be presented as an oral presentation; Bepirovirsen (ASO), a strategic collaboration product between Chia Tai Tianqing and GlaxoSmithKline (GSK), has been selected for 2 oral presentations and 8 poster presentations (including 1 distinguished poster).
SBP GROUP (01177) announced that a clinical study result for TQ-A3334 (TLR7 agonist), a National Class 1 innovative drug independently developed by the Company's subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Chia Tai Tianqing), has been selected as a late-breaking abstract (LBA) at the 2026 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) and will be presented as an oral presentation; Bepirovirsen (ASO), a strategic collaboration product between Chia Tai Tianqing and GlaxoSmithKline (GSK), has been selected for 2 oral presentations and 8 poster presentations (including 1 distinguished poster).
Related Articles
Guotai Haitong: Institutional optimization and improvement drive public mutual funds to shift from scale expansion to quality enhancement.
Guotai Haitong: Recommend overweighting large-cap style in October, with equal-weight allocation to value and growth styles.
YUK WING GP(01536): Rights Issue Under-Subscribed by Approximately 5.27%
Guotai Haitong: Institutional optimization and improvement drive public mutual funds to shift from scale expansion to quality enhancement.
Guotai Haitong: Recommend overweighting large-cap style in October, with equal-weight allocation to value and growth styles.
YUK WING GP(01536): Rights Issue Under-Subscribed by Approximately 5.27%
